Antilymphocyte induction immunosuppression in the post-Minnesota antilymphocyte globulin era: Incidence of renal dysfunction and delayed graft function. A single center experience

Clinical Transplantation

Volumn 10, Issue 3, 1996, Pages 237-242

  Malinow, Louis ^a   Walker, Jennifer ^a   Klassen, David ^a   Oldach, David ^b   Schweitzer, Eugene ^c   Bartlett, Stephen T ^c   Weir, Matthew R ^a,d  

^a Division of Nephrology   (United States)

^b Department of Medicine

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Antilymphocyte sera; Induction immunosuppression; Renal dysfunction

Indexed keywords

LYMPHOBLAST ANTIBODY; LYMPHOCYTE ANTIBODY; OKT 3; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; VIRUS INFECTION;

ADULT; ANTILYMPHOCYTE SERUM; CREATININE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; INTRAOPERATIVE CARE; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MUROMONAB-CD3; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS;

EID: 0030055704     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. HONG JH, SUMRANI N, CACCIARELLI TV, DISTANT D, SOMMER BG. Initiation of ALG pretransplant reduces the incidence of delayed renal allograft function. Transplant Proc 1993; 25: 581.
2. CLAESSON K, TUFVESON G, WAHLBERG J. Treatment with poly- and monoclonal antilymphocyteantibodies: Assessment of efficacy and safety in transplantation. Transplant Proc 1992; 24: 314
3. BEILMAN GJ, SHIELD CF, HUGHES JD, KELLEY HK, WARD LG, BECK D. The effects of intraoperative administration of OKT3 during renal transplantation. Transplantation 1993; 55: 490.
4. DEIERHOI MH, SOLLINGER HW, KALAYOGLU, BELZER FO, Quadruple therapy for cadaver renaltransplantation. Transplant Proc. 1987; 19: 1917.
5. ABOUNA GM, KUMAR MSA, STEPHAN R, et al. Induction therapy with antithymyocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation. Transplant Proc 1993; 25: 2241.
6. SOMMER BG, HENRY M, FERGUSON RM. Sequential antilymphoblast globulin and cyclosporine for renal transplantation. Transplantation 1987; 43: 85.
7. COSIMI AB, DELMONICO FL. Antilymphocyte antibody immunosuppressive therapy:, In: Kidney Transplant Rejection: Diagnosis and treatment. WILLIAMS GM, BURDICK JF, SOLEZ K. eds. New York and Basel:Mancel Dekker. Inc., 1986: 335.
8. NAJARIAN JS, SIMMONS RL, CONDIE RM, et al. Seven years experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg 1976; 184: 352.
9. NORMAN JD, CHATENOUD L, COHEN D, GOLDMAN M, SHIELD CF. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 1993; 25: 89.
10. ORTHO MULTICENTER TRANSPLANT STUDY GROUP. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
11. JEYARAJAH DR, THISTLETHWAITE JR. General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 1993;25 (Suppl 1): 1: 16.
12. THISTLETHWAITE JR, STUART JK, MAYES JT, et al. Complications and monitoring of OKT3 therapy. Am J Kid Dis 1988; 11: 112.
13. FIRST MR, SCHROEDER TJ, HARIHARAN S. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy). Transplant Proc 1993; 25 (Suppl 1): 25.
14. BATIUK TD, BENNETT WM, NORMAN DJ. Cytokine nephropathy during antilymphocyte therapy.Transplant Proc 1993; 25 (Suppl 2): 1: 27.
15. HOWARD RJ, PFAFF WW, BRUNSON ME, et al. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival. Transplant Proc 1993; 25 (Suppl 1): 884.
16. TOLEDOPEREYRA LH, WHITTEN JI. Comparison of the Incidence and effect of ATN in the cyclosporine and ALG eras. Transplant Proc 1988; 20: 910.
17. TERASAKI PI, CECKA JM, GJERTSON DW, et al. A ten-year prediction for kidney transplant survival. In: TERSAKI PI, CECKA JM, eds. Clinical Transplants 1992. Los Angeles: UCLA Tissue Typing Laboratory, 1992: 501.
18. THE CANADIAN MULTICENTER TRANSPLANT STUDY GROUP. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1986; 314: 1219.
19. ROBINSON ST, BARRY JM, NORMAN DJ. The hemodynamic effects of intraoperative injection of muromonab CD3. Transplantation 1993; 56: 356.
20. ABRAMOWICZ D, PRADIER O, MARCHANT A, et al. Induction of thromboses within renal graftsby high-dose prophylactic OKT3. Lancet 1992; 339: 777.
21. JONSSON J, LIGHT JA, KORB SM. Renal transplantation at the Washington Hospital Center. Experience with OKT3 and Minnesota antilymphoblast globulin for induction of immunosuppression. In: TERASAKI PI, ed. Clinical Transplants 1990. Los Angeles: UCLA Tissue Typing laboratory, 1990: 275.
22. ILLNER WD, THEODORAKIS J, ABENDROTH D, et al. Quadruple-drug induction therapy in combined renal and pancreatic transplantation- OKT3 versus ATG. Transplant Proc 1990; 22: 1586.
23. LIGHT JA, KHAWAND N, AQUINO A, ALI A, KORB S. Quadruple immunosuppression: Comparison of OKT3 and Minnesota Antilymphocyte globulin. Am J Kid Dis 1989; 14 (Suppl 2): 10.
24. HANTO DW, JENDRISAK MD, SO SKS, et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.Transplantation 1994; 57: 377.
25. BROYER M, GAGNADOUX MF, GUEST G, et al. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: A prospective, randomized study in 148 first cadaver kidney grafts. Transplant Proc 1993; 25: 570.
26. GRINO JM, CASTELAO AM, GONZALEZ C, et al. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA and steroids in cadaveric kidney transplantation Transplant Proc 1992; 24: 39.
27. SHIELD CF. Effective induction immunosuppression for cadaver renal transplantation at the St. Francis Regional Medical Center. In: TERASAKI PI, ed. Clinical Transplants 1990. Los Angeles: UCLA Tissue Typing Laboratory, 1990: 265.
28. YOTO Y, KUDOH T, ASANUMA H, et al. Transient disturbance of consciousness and hepatic dysfuction associated with human B19 infection. Lancet 1994; 344: 624.
29. CHORBA T, COCCIA P, HOLMAN RC, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (Fifth Disease). J Infect Dis 1986; 154: 383.
30. BARTOLOMEI CORSI O, ASSI A, et al. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol 1988; 25: 165.
31. LYON DJ, CHAPMAN CS, MARTIN C, et al. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet 1989; 1: 1085.
32. BROWN KE, ANDERSON SM, YOUNG NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262: 114.
33. VON HORN K, MORTIMER PP, YOUNG N, HANSON GR. Human parvovirus-associated red cell aplasia in the absence of underlying hemolytic anemia. Am J Pediatr Hematol Oncol 1986; 8: 235.
34. AZZI A, FANCI R, CIAPPI S, ZAKRZEWSKA K, BOSI A. Human parvovirus B19 infection in bone marrow transplantation patients. Am J Hematol 1993; 44: 207.
35. RAO SP, MILLER ST, COHEN BJ. Severe anemia due to B19 parvovirus infection in children with acute leukemia in remission. Am J Pediatr Hematol Oncol 1990; 12: 194.
36. KOCH WC, MASSEY G, RUSSEL CE, ADLER SP. Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients. J Pediatr 1990; 116: 355.
37. GRIFFIN TC, SQUIRES JE, TIMMONS CF, BUCHANAN GR. Chronic human parvovirus B19-induced erythroid hypoplasia as the initial manifestation of human immunodeficiency virus infection. J Pediatr 1991; 118: 899.
38. KURTZMAN GL, OZAWA K, COHEN BJ, et al. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987; 317: 287.
39. CHERNAK E, DUBIN G, HENRY D, et al. Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 20: 170.
40. GOTTLIEB F, DEUTSCH J. Red cell aplasia responsive to immunoglobulin therapy as initial manifestation of human immunodeficiency virus infection. Am J Med 1992; 92: 331.
41. KRAUSE JR, PENCHANSKY L, KNISELY AS. Morphological diagnosis of parvovirus B19 infection. Arch Pathol Lab Med 1992; 116: 178.
42. COLLINE RH, COOPER B, NIKAEIN M, KLINTMALM G, FAY JW. Graft versus host disease in a liver transplant recipient Ann Intern Med 1992; 11: 391.